Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view

Inovio Pharmaceuticals stock (ISIN US45773H2013) was quoted at around USD 1.12 on the Nasdaq Capital Market on September 16, 2026, leaving the DNA medicine specialist trading close to the midpoint of its 52-week range between USD 0.56 and USD 2.72 as investors assess its pipeline prospects and cash runway.

Analysts see upside from current levels

According to MarketBeat on September 16, 2026, analysts covering Inovio Pharmaceuticals have set an average price target of USD 3.17 for the stock, implying about 173 percent upside compared with a reference price of roughly USD 1.16 cited in the same overview.

As MarketBeat reports, this translates into a Moderate Buy consensus rating, with one strong buy, five buy, one hold and one sell recommendation contributing to an average rating score of 2.75 on its internal scale.

Stock performance and valuation context

Inovio Pharmaceuticals stock performance in 2026 has been weak despite the positive analyst stance. According to data summarized by MarketBeat on September 16, 2026, the shares started the year at USD 1.74 and have since fallen by about 33.3 percent to roughly USD 1.16.

This drawdown leaves the stock trading well below the consensus price target and below the upper end of its 52-week range of USD 0.56 to USD 2.72, which the same overview lists as the low and high levels reached over the last year, respectively.

Per the overview on MarketBeat dated September 16, 2026, Inovio Pharmaceuticals currently has a market capitalization of about USD 116.33 million at a price of roughly USD 1.12, underscoring that the company remains a small-cap biotech with meaningful sensitivity to trial milestones and financing decisions.

Investor sentiment signals from social activity

Beyond analyst reports, investor interest also shows up in social and alternative data. An overview of Stocktwits activity compiled by AltIndex on September 9, 2026, lists Inovio Pharmaceuticals among the more actively mentioned tickers in its sample, with 144 daily mentions accounting for 3.6 percent of total tracked posts that day.

A separate subscriber overview from AltIndex dated September 10, 2026, indicates that Inovio Pharmaceuticals has about 92,195 Stocktwits subscribers, pointing to a relatively large retail following compared with many micro-cap biotech peers.

Current trading snapshot and volatility

Intraday data from a Nasdaq-linked quote on September 16, 2026, shows Inovio Pharmaceuticals stock trading at around USD 1.09 as of 1:47 p.m. Eastern Time, down 6.06 percent on the day and illustrating the short-term volatility typical of small-cap biotech shares.

Another price snapshot embedded in a broader overview of health care stocks on a major financial portal cites Inovio Pharmaceuticals at USD 1.15 on September 16, 2026, reflecting a daily move of minus 0.86 percent and reinforcing the impression of modest declines against a backdrop of wider market weakness.

Next catalysts and risk considerations

Inovio Pharmaceuticals remains focused on developing DNA medicines, and upcoming clinical and corporate milestones are likely to drive the stock more than near-term macro moves. Investor conference participation noted in early September 2026 suggests the company is actively engaging with the investment community, but precise dates for the next quarterly earnings release or key trial readouts were not highlighted in the latest week-filtered sources.

For investors, the key tension is clear: the consensus price target of USD 3.17 offers substantial upside against a current price near USD 1.12, yet the roughly 33 percent year-to-date decline and small market capitalization around USD 116 million underline the execution and financing risks that can rapidly move Inovio Pharmaceuticals stock in either direction.

Stock level on Nasdaq

Inovio Pharmaceuticals stock most recently changed hands around USD 1.12 on the Nasdaq Capital Market on September 16, 2026, a level that sits roughly halfway between its 52-week low of USD 0.56 and high of USD 2.72 and leaves the shares well below the USD 3.17 average analyst price target.

More news and analyses on Inovio Pharmaceuticals stock